

ARE YOU ELIGIBLE FOR THE SPYRAL HTN CLINICAL TRIAL?

To be eligible for the SPYRAL HTN Clinical Trial Program, patients must be between the ages of 20 and 80 and have uncontrolled hypertension, with readings of:

- Systolic blood pressure (upper number) reading between 150 - 180 mm Hg.
- Diastolic blood pressure (lower number) reading above 90 mm Hg.
- If deemed eligible, participation is voluntary. Potential risks and benefits of being a participant in this clinical trial program should be discussed with your physician.

WHAT RESPONSIBILITIES DO PATIENTS IN THE TRIAL HAVE?

If you are eligible to participate in the SPYRAL HTN Clinical Trial Program, you will be required to:

- Attend regular clinic check-ups with your doctor.
- Wear a blood pressure monitoring cuff continuously for up to 24 hours at a time.
- You may also be required to consistently and reliably take your blood pressure medication for the duration of the study (although some patients may be able to stop taking their medication completely).

SPEAK WITH YOUR DOCTOR TO LEARN MORE ABOUT RENAL DENERVATION AND THE PRE-SCREENING STEPS.



References:

1. Hypertension, 2nd ed., H.R. Black, W.J. Elliott, 2013. Elsevier publishing. Pp 13-16.

Disclaimer: Individual results may vary. This information is designed to help you learn more about renal denervation. It is intended to provide you with helpful information but is for information purposes only, is not medical advice and should not be used as an alternative to speaking with your doctor. Be sure to discuss questions specific to your health and treatments with a healthcare professional. For more information, please speak to your healthcare professional. Limited by federal law to investigational use in the United States. Not for sale in the USA or Japan. For use by clinical investigators only. Trademarks may be registered and are the property of their respective owners. Copyright 2015 Medtronic, Inc. All rights reserved.

INTRODUCING AN INVESTIGATIONAL TREATMENT FOR HIGH BLOOD PRESSURE

SPYRAL HTN GLOBAL CLINICAL TRIAL PROGRAM



INFORMATION FOR PATIENTS



Medtronic
Further. Together



HOW THE RENAL NERVES INFLUENCE HIGH BLOOD PRESSURE¹

Research has shown that the kidneys play an important role in managing blood pressure. Sometimes, however, the nerves that control the kidney become over-active. This can cause the blood pressure to rise, leading to high blood pressure, also known as hypertension.


Knowing this, researchers developed an innovative procedure using an investigational device that uses energy to adjust the nerves that control the kidneys.

THE SPYRAL HTN GLOBAL CLINICAL TRIAL PROGRAM

The purpose of the SPYRAL HTN Global Clinical Trial Program is to provide information about the **safety and efficacy** of the investigational Symplicity Spyrals™ catheter and the Symplicity G3™ generator to help reduce blood pressure in patients whose blood pressure is not controlled despite lifestyle changes.




Guide catheter inserted into artery




Renal Denervation Symplicity Spyrals™ catheter delivers energy to artery

AN INNOVATIVE APPROACH TO LOWER BLOOD PRESSURE

Renal denervation is an investigational therapy that consists of a novel, minimally invasive procedure. Using active energy, overactive nerves that lead to the kidneys are adjusted from within each artery, potentially helping to balance overactive signaling. This procedure can be performed in a single session by inserting a tiny tube into the arteries leading to the kidneys. Following treatment, the device is removed. The single procedure offers the possibility of sustained blood pressure reduction.



Guide and Symplicity Spyrals™ catheter repositioned & treatment repeated into other artery



All devices are removed once treatment is delivered